Showing results (201-210 of 495) with videos related to

Sort By:
Pageof 50
BMJ (Clinical Research Ed.)|August 20, 2024
Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional studyAriadna Tibau, Thomas J Hwang, Jerry Avorn, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 8, 2024
Sales Revenues for New Therapeutic Agents Approved by the United States Food and Drug Administration From 1995 to 2014Olivier J Wouters, Aaron S Kesselheim, Jouni Kuha, et al.
Health Affairs (Project Hope)|August 5, 2024
Biosimilar Uptake In The US: Patient And Prescriber FactorsDongzhe Hong, Aaron S Kesselheim, Ameet Sarpatwari, et al.
Gene Therapy|November 7, 2023
Approval and therapeutic value of gene therapies in the US and EuropeKerstin N Vokinger, Camille E G Glaus, Aaron S Kesselheim
Journal of Pharmaceutical Policy and Practice|January 5, 2021
Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997Babak Sahragardjoonegani, Reed F Beall, Aaron S Kesselheim, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 28, 2021
Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based?Reed F Beall, Aidan Hollis, Aaron S Kesselheim, et al.
The Milbank Quarterly|August 10, 2021
Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing BoardsLiam Bendicksen, Benjamin N Rome, Jerry Avorn, et al.
Health Affairs (Project Hope)|August 2, 2021
Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent LitigationVictor L Van de Wiele, Aaron S Kesselheim, Ameet Sarpatwari
Plos Medicine|August 18, 2012
Conflict of interest reporting by authors involved in promotion of off-label drug use: an analysis of journal disclosuresAaron S Kesselheim, Bo Wang, David M Studdert, et al.
Pharmacoepidemiology and Drug Safety|August 17, 2020
Understanding when real world data can be used to replicate a clinical trial: A cross-sectional study of medications approved in 2011Michael Fralick, Emily Bartsch, Jonathan J Darrow, et al.
Pageof 50